NCT01285297终止不适用
A Prospective, Multicenter, Single Arm Study of Transmyocardial Revascularization (TMR) Plus Bone Marrow Aspirate Concentrated (BMAC) Using the Cardiogenesis PHOENIX Combination Handpiece Delivery System
Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.4 个研究点 分布在 2 个国家目标入组 7 人开始时间: 2010年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 7
- 试验地点
- 4
- 主要终点
- Mortality
研究概览
简要总结
The purpose of this study is to determine the safety of injecting autologous bone marrow concentrate with laser transmyocardial revascularization (TMR) for treatment of angina which cannot be treated by direct coronary intervention.
详细描述
Recently published information suggests the delivery of concentrated autologous bone marrow, in combination with transmyocardial revascularization (TMR) may provide synergistic effects for the reduction of angina in patients who are not treatable with conventional coronary artery bypass or percutaneous coronary intervention. This safety and feasibility study is intended to confirm the work previously done at one hospital in a larger, multicenter setting. Patients who are candidates for TMR will be asked to participate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient, 18 years of age or older, male or female.
- •Left ventricular ejection fraction greater than or equal to 40% (documented within 6 months of the TMR procedure.
- •Patient with medically refractory, stable, Class IV angina according to the Canadian Cardiovascular Society angina scale. Optimal medical therapy is defined as maximum tolerable and stable doses of beta-blockers, statins, anti-platelets and long acting nitrates without control of symptoms for at least 30 days.
- •Patient with at least a 15 cm² (or 15% of the surface area in the distal 2/3 of the left ventricle free wall to allow for a minimum of 15 TMR channels) documented region of the myocardium in the distal two-thirds of the left ventricle with reversible ischemia. Patients will be enrolled based on images used to determine eligibility for TMR within the previous 6 months. However, all patients will have baseline and follow-up MRIs taken per a standardized protocol and adjudicated by a core lab.
- •Has a documented left ventricular wall thickness of ≥8 mm.
- •Patient is not a candidate for treatment by direct coronary revascularization methods (i.e., CABG or PCI) as documented by an independent interventional cardiologist and an independent cardiothoracic surgeon on the Angiographic Screening Form.
- •Patient is able to perform the baseline exercise tolerance test (ETT).
- •Patient, if female, has no childbearing potential or has had a negative urine or serum pregnancy test within 7 days of the procedure.
- •Patient has a bone marrow aspirate total nucleated count of at least 15 x 106/mL at the time of harvest.
- •Patient has provided informed consent.
排除标准
- •Cannot undergo a surgical procedure, thoracotomy or general anesthesia.
- •Has any mechanical or prosthetic heart valve.
- •Has a history of bone marrow disease (especially Non-Hodgkin's Lymphoma and Myelodysplastic Syndrome) that prohibits autologous bone marrow derived cell transplantation.
- •Has severe, new onset or increasing angina. In addition, patients who cannot be weaned from intravenous anti-anginal medications for at least 48 hours preoperatively are to be excluded. Severe, new onset and increasing angina is defined as: Severe angina - angina occurring at rest and usually prolonged >20 minutes occurring within a week of presentation; new onset angina - angina of at least Canadian Cardiovascular Society Classification (CCSC) III severity with onset within 2 months of initial presentation; and increasing angina - previously diagnosed angina that is distinctly more frequent, longer in duration, or lower in threshold, (i.e., increased by at least one CCSC class within 2 months of initial presentation to at least CCSC III severity.
- •Has had a STEMI (ST Elevation Myocardial Infarction) or NSTEMI (Non-STEMI) within 4 weeks of the TMR procedure.
- •Has decompensated heart failure, or a diagnosis of NYHA Functional Class III/IV heart failure.
- •Has a hemorrhagic propensity that cannot be addressed with drug management.
- •Has severe or life-threatening arrhythmia (e.g., ventricular tachycardia or fibrillation) within one week prior to the TMR procedure.
- •Is unable to undergo a cardiac MRI procedure.
- •Has uncontrolled diabetes with HbA1C > 10%.
- •Has anemia defined as hematocrit < 33% in women and <39% in men.
- •Has moderate to severe renal dysfunction defined as serum creatinine >1.8 mg/dL.
- •Has moderate to severe liver dysfunction defined as> ALT/AST >5X the upper limit of normal.
- •Is unable or unwilling to return for follow-up.
- •Is participating in another clinical investigation within the prior 30 days.
结局指标
主要结局
Mortality
时间窗: One Year
All cause mortality
Major adverse cardiac and cerebral events (MACCE)
时间窗: One Year
MACCE is defined as cardiac death, cerebrovascular accidents, myocardial infarction, serious arrhythmia and congestive heart failure
次要结局
- Ejection Fraction(6 and 12 months)
- Exercise Tolerance Test(3, 6 and 12 months)
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
1 期
A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cell for the Treatment of Stroke.Stroke,NCT01832428Chaitanya Hospital, Pune50
进行中（未招募）
2 期
Autologous Stem Cell Study for Adult TBI (Phase 2b)Brain Injuries, TraumaticBrain Injuries, AcuteTBI (Traumatic Brain Injury)NCT02525432The University of Texas Health Science Center, Houston37
Unknown
1 期
Safety and Efficacy of Bone Marrow Derived Autologous Cells Treatment of Cerebral Palsy in Subjects Above 15 YearsAtaxic Infantile Cerebral PalsyNCT01834664Chaitanya Hospital, Pune100
Unknown
1 期
Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve DiseaseOptic AtrophyNCT01834079Chaitanya Hospital, Pune24
Unknown
1 期
Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Muscular Dystrophy.Muscular DystrophyDuchenne Muscular Dystrophy,NCT01834066Chaitanya Hospital, Pune25